The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases

Journal of Trace Elements in Medicine and Biology

Volumn 31, Issue , 2015, Pages 193-203

  Dusek, Petr ^a,b   Roos, Per M ^c,d   Litwin, Tomasz ^e   Schneider, Susanne A ^f   Flaten, Trond Peder ^g   Aaseth, Jan ^h  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d KAROLINSKA INSTITUTE   (Sweden)

^e INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^f UNIVERSITY OF KIEL   (Germany)

^g NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^h NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

Author keywords

Chelating agents; Copper; Iron; Manganese; Parkinson's disease; Wilson's disease

Indexed keywords

CERULOPLASMIN; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; FERRITIN; IRON; MANGANESE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN;

BRAIN CORTEX; BRAIN LEVEL; BRAIN REGION; CELL DAMAGE; CEREBROSPINAL FLUID; COPPER METABOLISM; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME SYNTHESIS; HOMEOSTASIS; HUMAN; IRON METABOLISM; IRON STORAGE; LONG TERM EXPOSURE; NERVE CELL; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SUBSTANTIA NIGRA; UPREGULATION; WILSON DISEASE; ADVERSE EFFECTS; ANIMAL; BRAIN; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BRAIN; COPPER; DISEASE MODELS, ANIMAL; ENVIRONMENTAL EXPOSURE; HEPATOLENTICULAR DEGENERATION; HOMEOSTASIS; HUMANS; IRON; MANGANESE; PARKINSON DISEASE;

EID: 84929654685     PISSN: 0946672X     EISSN: 18783252     Source Type: Journal    
DOI: 10.1016/j.jtemb.2014.05.007     Document Type: Review

References (214)

1. Halliwell B., Gutteridge J.M. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984, 219(1):1-14.
2. Morello M., Zatta P., Zambenedetti P., Martorana A., D'Angelo V., Melchiorri G., et al. Manganese intoxication decreases the expression of manganoproteins in the rat basal ganglia: an immunohistochemical study. Brain Res Bull 2007, 74(6):406-415.
3. Lill R., Hoffmann B., Molik S., Pierik A.J., Rietzschel N., Stehling O., et al. The role of mitochondria in cellular iron-sulfur protein biogenesis and iron metabolism. Biochim Biophys Acta 2012, 1823(9):1491-1508.
4. Zhang W., Phillips K., Wielgus A.R., Liu J., Albertini A., Zucca F.A., et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 2011, 19(1):63-72.
5. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem 2001, 276(47):44284-44296.
6. Chew K.C., Ang E.T., Tai Y.K., Tsang F., Lo S.Q., Ong E., et al. Enhanced autophagy from chronic toxicity of iron and mutant A53T alpha-synuclein: implications for neuronal cell death in Parkinson disease. J Biol Chem 2011, 286(38):33380-33389.
7. Wang X., Moualla D., Wright J.A., Brown D.R. Copper binding regulates intracellular alpha-synuclein localisation, aggregation and toxicity. J Neurochem 2010, 113(3):704-714.
8. Davies P., Moualla D., Brown D.R. Alpha-synuclein is a cellular ferrireductase. PLoS ONE 2011, 6(1):e15814.
9. Brown D.R. alpha-Synuclein as a ferrireductase. Biochem Soc Trans 2013, 41(6):1513-1517.
10. Castellani R.J., Siedlak S.L., Perry G., Smith M.A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol 2000, 100(2):111-114.
11. Zheng W., Monnot A.D. Regulation of brain iron and copper homeostasis by brain barrier systems: implication in neurodegenerative diseases. Pharmacol Ther 2012, 133(2):177-188.
12. Tuschl K., Mills P.B., Clayton P.T. Manganese and the brain. Int Rev Neurobiol 2013, 110:277-312.
13. Madsen E., Gitlin J.D. Copper and iron disorders of the brain. Annu Rev Neurosci 2007, 30:317-337.
14. Kristinsson J., Snaedal J., Torsdottir G., Johannesson T. Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: a synopsis of recent studies. Neuropsychiatr Dis Treat 2012, 8:515-521.
15. Zheng W., Aschner M., Ghersi-Egea J.F. Brain barrier systems: a new frontier in metal neurotoxicological research. Toxicol Appl Pharmacol 2003, 192(1):1-11.
16. Yokel R.A. Manganese flux across the blood-brain barrier. Neuromol Med 2009, 11(4):297-310.
17. Russo N., Edwards M., Andrews T., O'Brien M., Bhatia K.P. Hereditary haemochromatosis is unlikely to cause movement disorders - a critical review. J Neurol 2004, 251(7):849-852.
18. Nischwitz V., Berthele A., Michalke B. Speciation analysis of selected metals and determination of their total contents in paired serum and cerebrospinal fluid samples: an approach to investigate the permeability of the human blood-cerebrospinal fluid-barrier. Anal Chim Acta 2008, 627(2):258-269.
19. Bornhorst J., Wehe C.A., Huwel S., Karst U., Galla H.J., Schwerdtle T. Impact of manganese on and transfer across blood-brain and blood-cerebrospinal fluid barrier in vitro. J Biol Chem 2012, 287(21):17140-17151.
20. Yokel R.A., Crossgrove J.S. Manganese toxicokinetics at the blood-brain barrier. Res Rep Health Eff Inst 2004, 119:7-58. [discussion 59-73].
21. Michalke B., Berthele A., Mistriotis P., Ochsenkuhn-Petropoulou M., Halbach S. Manganese species from human serum, cerebrospinal fluid analyzed by size exclusion chromatography-, capillary electrophoresis coupled to inductively coupled plasma mass spectrometry. J Trace Elem Med Biol 2007, 21(Suppl. 1):4-9.
22. Michalke B., Lucio M., Berthele A., Kanawati B. Manganese speciation in paired serum and CSF samples using SEC-DRC-ICP-MS and CE-ICP-DRC-MS. Anal Bioanal Chem 2013, 405(7):2301-2309.
23. Aschner M., Gannon M. Manganese (Mn) transport across the rat blood-brain barrier: saturable and transferrin-dependent transport mechanisms. Brain Res Bull 1994, 33(3):345-349.
24. Fitsanakis V.A., Zhang N., Garcia S., Aschner M. Manganese (Mn) and iron (Fe): interdependency of transport and regulation. Neurotox Res 2010, 18(2):124-131.
25. Mena I., Horiuchi K., Burke K., Cotzias G.C. Chronic manganese poisoning. Individual susceptibility and absorption of iron. Neurology 1969, 19(10):1000-1006.
26. Erikson K.M., Syversen T., Steinnes E., Aschner M. Globus pallidus: a target brain region for divalent metal accumulation associated with dietary iron deficiency. J Nutr Biochem 2004, 15(6):335-341.
27. Erikson K.M., Syversen T., Aschner J.L., Aschner M. Interactions between excessive manganese exposures and dietary iron-deficiency in neurodegeneration. Environ Toxicol Pharmacol 2005, 19(3):415-421.
28. Wang X., Li G.J., Zheng W. Upregulation of DMT1 expression in choroidal epithelia of the blood-CSF barrier following manganese exposure in vitro. Brain Res 2006, 1097(1):1-10.
29. Crossgrove J.S., Yokel R.A. Manganese distribution across the blood-brain barrier III. The divalent metal transporter-1 is not the major mechanism mediating brain manganese uptake. Neurotoxicology 2004, 25(3):451-460.
30. Thompson K., Molina R.M., Donaghey T., Schwob J.E., Brain J.D., Wessling-Resnick M. Olfactory uptake of manganese requires DMT1 and is enhanced by anemia. FASEB J 2007, 21(1):223-230.
31. Monnot A.D., Zheng G., Zheng W. Mechanism of copper transport at the blood-cerebrospinal fluid barrier: influence of iron deficiency in an in vitro model. Exp Biol Med (Maywood) 2012, 237(3):327-333.
32. Gaasch J.A., Geldenhuys W.J., Lockman P.R., Allen D.D., Van der Schyf C.J. Voltage-gated calcium channels provide an alternate route for iron uptake in neuronal cell cultures. Neurochem Res 2007, 32(10):1686-1693.
33. Michalke B., Fernsebner K. New insights into manganese toxicity and speciation. J Trace Elem Med Biol 2014, 28(2):106-116.
34. Graham D.G. Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology 1984, 5(1):83-95.
35. Dick F.D., De Palma G., Ahmadi A., Scott N.W., Prescott G.J., Bennett J., et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. Occup Environ Med 2007, 64(10):666-672.
36. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997, 48(3):650-658.
37. Zayed J., Ducic S., Campanella G., Panisset J.C., Andre P., Masson H., et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci 1990, 17(3):286-291.
38. Racette B.A., Aschner M., Guilarte T.R., Dydak U., Criswell S.R., Zheng W. Pathophysiology of manganese-associated neurotoxicity. Neurotoxicology 2012, 33(4):881-886.
39. Aschner M., Erikson K.M., Herrero Hernandez E., Tjalkens R. Manganese and its role in Parkinson's disease: from transport to neuropathology. Neuromol Med 2009, 11(4):252-266.
40. Maeda H., Sato M., Yoshikawa A., Kimura M., Sonomura T., Terada M., et al. Brain MR imaging in patients with hepatic cirrhosis: relationship between high intensity signal in basal ganglia on T1-weighted images and elemental concentrations in brain. Neuroradiology 1997, 39(8):546-550.
41. Perl D.P., Olanow C.W. The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol 2007, 66(8):675-682.
42. Koller W.C., Lyons K.E., Truly W. Effect of levodopa treatment for parkinsonism in welders: a double-blind study. Neurology 2004, 62(5):730-733.
43. Lucchini R.G., Martin C.J., Doney B.C. From manganism to manganese-induced parkinsonism: a conceptual model based on the evolution of exposure. Neuromol Med 2009, 11(4):311-321.
44. Finkelstein M.M., Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res 2007, 104(3):420-432.
45. Willis A.W., Evanoff B.A., Lian M., Galarza A., Wegrzyn A., Schootman M., et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol 2010, 172(12):1357-1363.
46. Gorell J.M., Rybicki B.A., Cole Johnson C., Peterson E.L. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 1999, 18(6):303-308.
47. Hudnell H.K. Effects from environmental Mn exposures: a review of the evidence from non-occupational exposure studies. Neurotoxicology 1999, 20(2-3):379-397.
48. Lucchini R.G., Albini E., Benedetti L., Borghesi S., Coccaglio R., Malara E.C., et al. High prevalence of Parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries. Am J Ind Med 2007, 50(11):788-800.
49. Racette B.A., McGee-Minnich L., Moerlein S.M., Mink J.W., Videen T.O., Perlmutter J.S. Welding-related parkinsonism: clinical features, treatment, and pathophysiology. Neurology 2001, 56(1):8-13.
50. Fored C.M., Fryzek J.P., Brandt L., Nise G., Sjogren B., McLaughlin J.K., et al. Parkinson's disease and other basal ganglia or movement disorders in a large nationwide cohort of Swedish welders. Occup Environ Med 2006, 63(2):135-140.
51. Kenborg L., Lassen C.F., Hansen J., Olsen J.H. Parkinson's disease and other neurodegenerative disorders among welders: a Danish cohort study. Mov Disord 2012, 27(10):1283-1289.
52. Guilarte T.R. Manganese and Parkinson's disease: a critical review and new findings. Environ Health Perspect 2010, 118(8):1071-1080.
53. Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 2005, 64(12):2021-2028.
54. Mortimer J.A., Borenstein A.R., Nelson L.M. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology 2012, 79(11):1174-1180.
55. Park R.M. Neurobehavioral deficits and parkinsonism in occupations with manganese exposure: a review of methodological issues in the epidemiological literature. Saf Health Work 2013, 4(3):123-135.
56. Wesemann W., Blaschke S., Solbach M., Grote C., Clement H.W., Riederer P. Intranigral injected iron progressively reduces striatal dopamine metabolism. J Neural Transm Park Dis Dement Sect 1994, 8(3):209-214.
57. Sengstock G.J., Olanow C.W., Menzies R.A., Dunn A.J., Arendash G.W. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993, 35(1):67-82.
58. Jiang H., Song N., Wang J., Ren L.Y., Xie J.X. Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra. Neurochem Int 2007, 51(1):32-36.
59. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N., et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci Lett 1994, 168(1-2):251-253.
60. Temlett J.A., Landsberg J.P., Watt F., Grime G.W. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 1994, 62(1):134-146.
61. Ayton S., Lei P., Duce J.A., Wong B.X., Sedjahtera A., Adlard P.A., et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 2013, 73(4):554-559.
62. He Y., Thong P.S., Lee T., Leong S.K., Mao B.Y., Dong F., et al. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med 2003, 35(5):540-547.
63. Shachar D.B., Kahana N., Kampel V., Warshawsky A., Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004, 46(2):254-263.
64. Berg D., Hochstrasser H. Iron metabolism in Parkinsonian syndromes. Mov Disord 2006, 21(9):1299-1310.
65. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 1991, 56(4):1441-1444.
66. Youdim M.B., Stephenson G., Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 2004, 1012:306-325.
67. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 2007, 21(14):3835-3844.
68. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37(6):899-909.
69. Devos D., Moreau C., Devedjian J.C., Kluza J., Petrault M., Laloux C., et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014, ahead of print. 10.1089/ars.2013.5593.
70. Salazar J., Mena N., Hunot S., Prigent A., Alvarez-Fischer D., Arredondo M., et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A 2008, 105(47):18578-18583.
71. Brouillet E.P., Shinobu L., McGarvey U., Hochberg F., Beal M.F. Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Exp Neurol 1993, 120(1):89-94.
72. Cordova F.M., Aguiar A.S., Peres T.V., Lopes M.W., Goncalves F.M., Pedro D.Z., et al. Manganese-exposed developing rats display motor deficits and striatal oxidative stress that are reversed by Trolox. Arch Toxicol 2013, 87(7):1231-1244.
73. Stanwood G.D., Leitch D.B., Savchenko V., Wu J., Fitsanakis V.A., Anderson D.J., et al. Manganese exposure is cytotoxic and alters dopaminergic and GABAergic neurons within the basal ganglia. J Neurochem 2009, 110(1):378-389.
74. Sanchez-Betancourt J., Anaya-Martinez V., Gutierrez-Valdez A.L., Ordonez-Librado J.L., Montiel-Flores E., Espinosa-Villanueva J., et al. Manganese mixture inhalation is a reliable Parkinson disease model in rats. Neurotoxicology 2012, 33(5):1346-1355.
75. Friedman A., Galazka-Friedman J., Koziorowski D. Iron as a cause of Parkinson disease - a myth or a well established hypothesis?. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S212-S214.
76. Sian-Hulsmann J., Mandel S., Youdim M.B., Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011, 118(6):939-957.
77. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989, 52(2):515-520.
78. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991, 114(Pt 4):1953-1975.
79. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987, 2(8569):1219-1220.
80. Earle K.M. Studies on Parkinson's disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 1968, 27(1):1-14.
81. Good P.F., Olanow C.W., Perl D.P. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992, 593(2):343-346.
82. Griffiths P.D., Crossman A.R. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993, 4(2):61-65.
83. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991, 56(2):446-451.
84. Jellinger K., Kienzl E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J Neurochem 1992, 59(3):1168-1171.
85. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., et al. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 1994, 36(6):876-881.
86. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., et al. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 2007, 68(21):1820-1825.
87. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988, 74(3):199-205.
88. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 1999, 122(Pt 4):667-673.
89. Galazka-Friedman J., Bauminger E.R., Friedman A., Barcikowska M., Hechel D., Nowik I. Iron in parkinsonian and control substantia nigra - a Mossbauer spectroscopy study. Mov Disord 1996, 11(1):8-16.
90. Wypijewska A., Galazka-Friedman J., Bauminger E.R., Wszolek Z.K., Schweitzer K.J., Dickson D.W., et al. Iron and reactive oxygen species activity in parkinsonian substantia nigra. Parkinsonism Relat Disord 2010, 16(5):329-333.
91. Hare D.J., Gerlach M., Riederer P. Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients. J Neural Transm 2012, 119(12):1515-1521.
92. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., et al. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem 1995, 65(2):710-716.
93. Palmer J.H., Sapienza T.J., Zink E.W. Pyrazinamide interference in the Ferrochem II determination of iron. Clin Chem 1988, 34(7):1510-1511.
94. Danielisova V., Gottlieb M., Burda J. Iron deposition after transient forebrain ischemia in rat brain. Neurochem Res 2002, 27(3):237-242.
95. Versieck J., Barbier F., Cornelis R., Hoste J. Sample contamination as a source of error in trace-element analysis of biological samples. Talanta 1982, 29(11 Pt 2):973-984.
96. Versieck J., Vanballenberghe L., De Kesel A., Van Renterghem D. Accuracy of biological trace-element determinations. Biol Trace Elem Res 1987, 12(1):45-54.
97. Twomey P.J., Viljoen A., House I.M., Reynolds T.M., Wierzbicki A.S. Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. Clin Chem 2005, 51(8):1558-1559.
98. Wedler F.C., Denman R.B. Glutamine synthetase: the major Mn(II) enzyme in mammalian brain. Curr Top Cell Regul 1984, 24:153-169.
99. Michalke B. Manganese speciation using capillary electrophoresis-ICP-mass spectrometry. J Chromatogr A 2004, 1050(1):69-76.
100. Quintana M., Klouda A.D., Gondikas A., Ochsenkuhn-Petropoulou M., Michalke B. Analysis of size characterized manganese species from liver extracts using capillary zone electrophoresis coupled to inductively coupled plasma mass spectrometry (CZE-ICP-MS). Anal Chim Acta 2006, 573-574:172-180.
101. Michalke B., Halbach S., Nischwitz V. Speciation and toxicological relevance of manganese in humans. J Environ Monit 2007, 9(7):650-656.
102. Davies K.M., Bohic S., Carmona A., Ortega R., Cottam V., Hare D.J., et al. Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol Aging 2014, 35(4):858-866.
103. Friedman A., Arosio P., Finazzi D., Koziorowski D., Galazka-Friedman J. Ferritin as an important player in neurodegeneration. Parkinsonism Relat Disord 2011, 17(6):423-430.
104. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., et al. Decreased ferritin levels in brain in Parkinson's disease. J Neurochem 1990, 55(1):16-20.
105. Visanji N.P., Collingwood J.F., Finnegan M.E., Tandon A., House E., Hazrati L.N. Iron deficiency in parkinsonism: region-specific iron dysregulation in Parkinson's disease and multiple system atrophy. J Parkinsons Dis 2013, 3(4):523-537.
106. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., Agid Y., et al. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J Neurochem 2002, 83(2):320-330.
107. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., et al. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001, 76(6):1766-1773.
108. Tribl F., Asan E., Arzberger T., Tatschner T., Langenfeld E., Meyer H.E., et al. Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach. Mol Cell Proteomics 2009, 8(8):1832-1838.
109. Faucheux B.A., Martin M.E., Beaumont C., Hauw J.J., Agid Y., Hirsch E.C. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J Neurochem 2003, 86(5):1142-1148.
110. Zecca L., Wilms H., Geick S., Claasen J.H., Brandenburg L.O., Holzknecht C., et al. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. Acta Neuropathol 2008, 116(1):47-55.
111. Fernsebner K., Zorn J., Kanawati B., Walker A., Michalke B. Manganese leads to an increase in markers of oxidative stress as well as to a shift in the ratio of Fe(II)/(III) in rat brain tissue. Metallomics 2014, 6(4):921-931.
112. Chwiej J., Adamek D., Szczerbowska-Boruchowska M., Krygowska-Wajs A., Wojcik S., Falkenberg G., et al. Investigations of differences in iron oxidation state inside single neurons from substantia nigra of Parkinson's disease and control patients using the micro-XANES technique. J Biol Inorg Chem 2007, 12(2):204-211.
113. Friedman A., Galazka-Friedman J. The history of the research of iron in parkinsonian substantia nigra. J Neural Transm 2012, 119(12):1507-1510.
114. Morris C.M., Candy J.M., Oakley A.E., Bloxham C.A., Edwardson J.A. Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) 1992, 144(3):235-257.
115. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004, 5(11):863-873.
116. Yu X., Du T., Song N., He Q., Shen Y., Jiang H., et al. Decreased iron levels in the temporal cortex in postmortem human brains with Parkinson disease. Neurology 2013, 80(5):492-495.
117. Popescu B.F., George M.J., Bergmann U., Garachtchenko A.V., Kelly M.E., McCrea R.P., et al. Mapping metals in Parkinson's and normal brain using rapid-scanning X-ray fluorescence. Phys Med Biol 2009, 54(3):651-663.
118. Gazzaniga G.C., Ferraro B., Camerlingo M., Casto L., Viscardi M., Mamoli A. A case control study of CSF copper, iron and manganese in Parkinson disease. Ital J Neurol Sci 1992, 13(3):239-243.
119. Hozumi I., Hasegawa T., Honda A., Ozawa K., Hayashi Y., Hashimoto K., et al. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci 2011, 303(1-2):95-99.
120. Pall H.S., Williams A.C., Blake D.R., Lunec J., Gutteridge J.M., Hall M., et al. Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 1987, 2(8553):238-241.
121. Jimenez-Jimenez F.J., Molina J.A., Aguilar M.V., Meseguer I., Mateos-Vega C.J., Gonzalez-Munoz M.J., et al. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J Neural Transm 1998, 105(4-5):497-505.
122. Alimonti A., Bocca B., Pino A., Ruggieri F., Forte G., Sancesario G. Elemental profile of cerebrospinal fluid in patients with Parkinson's disease. J Trace Elem Med Biol 2007, 21(4):234-241.
123. Bocca B., Alimonti A., Senofonte O., Pino A., Violante N., Petrucci F., et al. Metal changes in CSF and peripheral compartments of parkinsonian patients. J Neurol Sci 2006, 248(1-2):23-30.
124. Forte G., Bocca B., Senofonte O., Petrucci F., Brusa L., Stanzione P., et al. Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004, 111(8):1031-1040.
125. Boll M.C., Sotelo J., Otero E., Alcaraz-Zubeldia M., Rios C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett 1999, 265(3):155-158.
126. Funke C., Schneider S.A., Berg D., Kell D.B. Genetics and iron in the systems biology of Parkinson's disease and some related disorders. Neurochem Int 2013, 62(5):637-652.
127. He Q., Du T., Yu X., Xie A., Song N., Kang Q., et al. DMT1 polymorphism and risk of Parkinson's disease. Neurosci Lett 2011, 501(3):128-131.
128. Borie C., Gasparini F., Verpillat P., Bonnet A.M., Agid Y., Hetet G., et al. French Parkinson's disease genetic study g. Association study between iron-related genes polymorphisms and Parkinson's disease. J Neurol 2002, 249(7):801-804.
129. Hochstrasser H., Bauer P., Walter U., Behnke S., Spiegel J., Csoti I., et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004, 63(10):1912-1917.
130. Torsdottir G., Sveinbjornsdottir S., Kristinsson J., Snaedal J., Johannesson T. Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study. J Neurol Sci 2006, 241(1-2):53-58.
131. Torsdottir G., Kristinsson J., Sveinbjornsdottir S., Snaedal J., Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol 1999, 85(5):239-243.
132. Boll M.C., Alcaraz-Zubeldia M., Montes S., Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 2008, 33(9):1717-1723.
133. Olivieri S., Conti A., Iannaccone S., Cannistraci C.V., Campanella A., Barbariga M., et al. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 2011, 31(50):18568-18577.
134. Bharucha K.J., Friedman J.K., Vincent A.S., Ross E.D. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol 2008, 255(12):1957-1962.
135. Jin L., Wang J., Jin H., Fei G., Zhang Y., Chen W., et al. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease. Eur J Neurol 2012, 19(7):969-976.
136. Jin L., Wang J., Zhao L., Jin H., Fei G., Zhang Y., et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011, 134(Pt 1):50-58.
137. Martinez-Hernandez R., Montes S., Higuera-Calleja J., Yescas P., Boll M.C., Diaz-Ruiz A., et al. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study. Neurochem Res 2011, 36(11):2111-2115.
138. Ke Y., Qian Z.M. Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol 2007, 83(3):149-173.
139. Faucheux B.A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc Natl Acad Sci U S A 1995, 92(21):9603-9607.
140. Wang J., Jiang H., Xie J.X. Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats. Eur J Neurosci 2007, 25(9):2766-2772.
141. Crichton R.R., Dexter D.T., Ward R.J. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm 2011, 118(3):301-314.
142. Gille G., Reichmann H. Iron-dependent functions of mitochondria-relation to neurodegeneration. J Neural Transm 2011, 118(3):349-359.
143. Li X.P., Xie W.J., Zhang Z., Kansara S., Jankovic J., Le W.D. A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals 2012, 20(4):223-236.
144. Larner F., Sampson B., Rehkamper M., Weiss D.J., Dainty J.R., O'Riordan S., et al. High precision isotope measurements reveal poor control of copper metabolism in parkinsonism. Metallomics 2013, 5(2):125-132.
145. Davies K.M., Hare D.J., Cottam V., Chen N., Hilgers L., Halliday G., et al. Localization of copper and copper transporters in the human brain. Metallomics 2013, 5(1):43-51.
146. Uitti R.J., Rajput A.H., Rozdilsky B., Bickis M., Wollin T., Yuen W.K. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains. Can J Neurol Sci 1989, 16(3):310-314.
147. Choi B.S., Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res 2009, 1248:14-21.
148. Tanzi R.E., Petrukhin K., Chernov I., Pellequer J.L., Wasco W., Ross B., et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993, 5(4):344-350.
149. Telianidis J., Hung Y.H., Materia S., Fontaine S.L. Role of the P-Type ATPases, ATP7A and ATP7B in brain copper homeostasis. Front Aging Neurosci 2013, 5:44.
150. Zischka H., Lichtmannegger J., Schmitt S., Jagemann N., Schulz S., Wartini D., et al. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J Clin Invest 2011, 121(4):1508-1518.
151. Hayashi H., Yano M., Fujita Y., Wakusawa S. Compound overload of copper and iron in patients with Wilson's disease. Med Mol Morphol 2006, 39(3):121-126.
152. Barnes N., Tsivkovskii R., Tsivkovskaia N., Lutsenko S. The copper-transporting ATPases, Menkes and Wilson disease proteins, have distinct roles in adult and developing cerebellum. J Biol Chem 2005, 280(10):9640-9645.
153. Kodama H., Okabe I., Yanagisawa M., Nomiyama H., Nomiyama K., Nose O., et al. Does CSF copper level in Wilson disease reflect copper accumulation in the brain?. Pediatr Neurol 1988, 4(1):35-37.
154. Weisner B., Hartard C., Dieu C. CSF copper concentration: a new parameter for diagnosis and monitoring therapy of Wilson's disease with cerebral manifestation. J Neurol Sci 1987, 79(1-2):229-237.
155. Stuerenburg H.J., copper concentrations C.S.F. blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson's disease. J Neural Transm 2000, 107(3):321-329.
156. Stuerenburg H.J., Eggers C. Early detection of non-compliance in Wilson's disease by consecutive copper determination in cerebrospinal fluid. J Neurol Neurosurg Psychiatry 2000, 69(5):701-702.
157. Litwin T., Gromadzka G., Szpak G.M., Jablonka-Salach K., Bulska E., Czlonkowska A. Brain metal accumulation in Wilson's disease. J Neurol Sci 2013, 329(1-2):55-58.
158. Cumings J.N. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 1948, 71(Pt. 4):410-415.
159. Faa G., Lisci M., Caria M.P., Ambu R., Sciot R., Nurchi V.M., et al. Brain copper, iron, magnesium, zinc, calcium, sulfur and phosphorus storage in Wilson's disease. J Trace Elem Med Biol 2001, 15(2-3):155-160.
160. Horoupian D.S., Sternlieb I., Scheinberg I.H. Neuropathological findings in penicillamine-treated patients with Wilson's disease. Clin Neuropathol 1988, 7(2):62-67.
161. Sinha S., Taly A.B., Ravishankar S., Prashanth L.K., Venugopal K.S., Arunodaya G.R., et al. Wilson's disease: cranial MRI observations and clinical correlation. Neuroradiology 2006, 48(9):613-621.
162. Sinha S., Taly A.B., Prashanth L.K., Ravishankar S., Arunodaya G.R., Vasudev M.K. Sequential MRI changes in Wilson's disease with de-coppering therapy: a study of 50 patients. Br J Radiol 2007, 80(957):744-749.
163. Skowronska M., Litwin T., Dziezyc K., Wierzchowska A., Czlonkowska A. Does brain degeneration in Wilson disease involve not only copper but also iron accumulation?. Neurol Neurochir Pol 2013, 47(6):542-546.
164. Lee J.H., Yang T.I., Cho M., Yoon K.T., Baik S.K., Han Y.H. Widespread cerebral cortical mineralization in Wilson's disease detected by susceptibility-weighted imaging. J Neurol Sci 2012, 313(1-2):54-56.
165. Engelbrecht V., Schlaug G., Hefter H., Kahn T., Modder U. MRI of the brain in Wilson disease: T2 signal loss under therapy. J Comput Assist Tomogr 1995, 19(4):635-638.
166. Brugieres P., Combes C., Ricolfi F., Degos J.D., Poirier J., Gaston A. Atypical MR presentation of Wilson disease: a possible consequence of paramagnetic effect of copper?. Neuroradiology 1992, 34(3):222-224.
167. Mironov A. Decreased signal intensity of the putamen and the caudate nucleus in Wilson disease of the brain. Neuroradiology 1993, 35(2):166.
168. Fritzsch D., Reiss-Zimmermann M., Trampel R., Turner R., Hoffmann K.T., Schafer A. Seven-Tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Invest Radiol 2014, 49(5):299-306.
169. 52Fe-citrate PET study. J Nucl Med 2000, 41(5):781-787.
170. Ragan H.A., Nacht S., Lee G.R., Bishop C.R., Cartwright G.E. Effect of ceruloplasmin on plasma iron in copper-deficient swine. Am J Physiol 1969, 217(5):1320-1323.
171. Osaki S., Johnson D.A., Frieden E. The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I. J Biol Chem 1971, 246(9):3018-3023.
172. Roeser H.P., Lee G.R., Nacht S., Cartwright G.E. The role of ceruloplasmin in iron metabolism. J Clin Invest 1970, 49(12):2408-2417.
173. Pfeiffenberger J., Gotthardt D.N., Herrmann T., Seessle J., Merle U., Schirmacher P., et al. Iron metabolism and the role of HFE gene polymorphisms in Wilson disease. Liver Int 2012, 32(1):165-170.
174. Medici V., Di Leo V., Lamboglia F., Bowlus C.L., Tseng S.C., D'Inca R., et al. Effect of penicillamine and zinc on iron metabolism in Wilson's disease. Scand J Gastroenterol 2007, 42(12):1495-1500.
175. Jursa T., Smith D.R. Ceruloplasmin alters the tissue disposition and neurotoxicity of manganese, but not its loading onto transferrin. Toxicol Sci 2009, 107(1):182-193.
176. Wu J., Forbes J.R., Chen H.S., Cox D.W. The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat Genet 1994, 7(4):541-545.
177. Theophilos M.B., Cox D.W., Mercer J.F. The toxic milk mouse is a murine model of Wilson disease. Hum Mol Genet 1996, 5(10):1619-1624.
178. Buiakova O.I., Xu J., Lutsenko S., Zeitlin S., Das K., Das S., et al. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet 1999, 8(9):1665-1671.
179. Suzuki K.T. Disordered copper metabolism in LEC rats, an animal model of Wilson disease: roles of metallothionein. Res Commun Mol Pathol Pharmacol 1995, 89(2):221-240.
180. Koizumi M., Fujii J., Suzuki K., Inoue T., Inoue T., Gutteridge J.M., et al. A marked increase in free copper levels in the plasma and liver of LEC rats: an animal model for Wilson disease and liver cancer. Free Radic Res 1998, 28(5):441-450.
181. Suzuki K.T., Kanno S., Misawa S., Sumi Y. Changes in hepatic copper distribution leading to hepatitis in LEC rats. Res Commun Chem Pathol Pharmacol 1993, 82(2):217-224.
182. Kim J.M., Ko S.B., Kwon S.J., Kim H.J., Han M.K., Kim D.W., et al. Ferrous and ferric iron accumulates in the brain of aged Long-Evans Cinnamon rats, an animal model of Wilson's disease. Neurosci Lett 2005, 382(1-2):143-147.
183. Sugawara N., Ohta T., Lai Y.R., Sugawara C., Yuasa M., Nakamura M., et al. Iron depletion prevents adenine nucleotide decomposition and an increase of xanthine oxidase activity in the liver of the Long Evans Cinnamon (LEC) rat, an animal model of Wilson's disease. Life Sci 1999, 65(13):1423-1431.
184. Hayashi H., Wakusawa S., Yano M. Iron removal by phlebotomy for the prophylaxis of fulminant hepatitis in a Wilson disease model of Long-Evans Cinnamon Rats. Hepatol Res 2006, 35(4):276-280.
185. Santon A., Irato P., Medici V., D'Inca R., Albergoni V., Sturniolo G.C. Effect and possible role of Zn treatment in LEC rats, an animal model of Wilson's disease. Biochim Biophys Acta 2003, 1637(1):91-97.
186. Allen K.J., Buck N.E., Cheah D.M., Gazeas S., Bhathal P., Mercer J.F. Chronological changes in tissue copper, zinc and iron in the toxic milk mouse and effects of copper loading. Biometals 2006, 19(5):555-564.
187. Przybylkowski A., Gromadzka G., Wawer A., Bulska E., Jablonka-Salach K., Grygorowicz T., et al. Neurochemical and behavioral characteristics of toxic milk mice: an animal model of Wilson's disease. Neurochem Res 2013, 38(10):2037-2045.
188. Chen D.B., Feng L., Lin X.P., Zhang W., Li F.R., Liang X.L., et al. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. PLoS ONE 2012, 7(5):e37709.
189. 2. Mol Imaging Biol 2012, 14(5):600-607.
190. Merle U., Tuma S., Herrmann T., Muntean V., Volkmann M., Gehrke S.G., et al. Evidence for a critical role of ceruloplasmin oxidase activity in iron metabolism of Wilson disease gene knockout mice. J Gastroenterol Hepatol 2010, 25(6):1144-1150.
191. Pal A., Vasishta R., Prasad R. Hepatic and hippocampus iron status is not altered in response to increased serum ceruloplasmin and serum "free" copper in Wistar rat model for non-Wilsonian brain copper toxicosis. Biol Trace Elem Res 2013, 154(3):403-411.
192. Chakraborty S., Aschner M. Altered manganese homeostasis: implications for BLI-3-dependent dopaminergic neurodegeneration and SKN-1 protection in C. elegans. J Trace Elem Med Biol 2012, 26(2-3):183-187.
193. Kim Y. High signal intensities on T1-weighted MRI as a biomarker of exposure to manganese. Ind Health 2004, 42(2):111-115.
194. Sikk K., Haldre S., Aquilonius S.M., Asser A., Paris M., Roose A., et al. Manganese-induced parkinsonism in methcathinone abusers: bio-markers of exposure and follow-up. Eur J Neurol 2013, 20(6):915-920.
195. Jellinger K.A. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012, 27(1):8-30.
196. Ayton S., Lei P. Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int 2014, 2014:581256.
197. Cabantchik Z.I., Munnich A., Youdim M.B., Devos D. Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol 2013, 4:167.
198. Beal M.F., Oakes D., Shoulson I., Henchcliffe C., Galpern W.R., Haas R., et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 2014, 71(5):543-552.
199. Persson T., Popescu B.O., Cedazo-Minguez A. Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?. Oxid Med Cell Longev 2014, 2014:427318.
200. Shoulson I. DATATOP: a decade of neuroprotective inquiry, Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann Neurol 1998, 44(3 Suppl. 1):S160-S166.
201. Zaitone S.A., Abo-Elmatty D.M., Shaalan A.A. Acetyl-l-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. Pharmacol Biochem Behav 2012, 100(3):347-360.
202. Squitti R. Metals in Alzheimer's disease: a systemic perspective. Front Biosci (Landmark Ed) 2012, 17:451-472.
203. Roos P.M., Vesterberg O., Syversen T., Flaten T.P., Nordberg M. Metal concentrations in cerebrospinal fluid and blood plasma from patients with amyotrophic lateral sclerosis. Biol Trace Elem Res 2013, 151(2):159-170.
204. Stamelou M., Tuschl K., Chong W.K., Burroughs A.K., Mills P.B., Bhatia K.P., et al. Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder. Mov Disord 2012, 27(10):1317-1322.
205. 2EDTA. Neurotoxicology 2006, 27(3):333-339.
206. Hininger I., Waters R., Osman M., Garrel C., Fernholz K., Roussel A.M., et al. Acute prooxidant effects of vitamin C in EDTA chelation therapy and long-term antioxidant benefits of therapy. Free Radic Biol Med 2005, 38(12):1565-1570.
207. Crisponi G., Nurchi V.M., Fanni D., Gerosa C., Nemolato S., Faa G. Copper-related diseases: from chemistry to molecular pathology. Coord Chem Rev 2010, 254(7-8):876-889.
208. Szczerbowska-Boruchowska M., Krygowska-Wajs A., Adamek D. Elemental micro-imaging and quantification of human substantia nigra using synchrotron radiation based x-ray fluorescence--in relation to Parkinson's disease. J Phys Condens Matter 2012, 24(24):244104.
209. Szczerbowska-Boruchowska M., Lankosz M., Ostachowicz J., Adamek D., Krygowska-Wajs A., Tomik B., Szczudlik A., Simionovici A., Bohic S. Topographic and quantitative microanalysis of human central nervous system tissue using synchrotron radiation. X-Ray Spectrometry 2004, 33(1):3-11.
210. Barapatre N, Morawski M, Butz T, Reinert T. Trace element mapping in Parkinsonian brain by quantitative ion beam microscopy. Nuclear Instruments & Methods in Physics Research Section B-Beam Interactions with Materials and Atoms 2010;268(11-12): 2156-2159.
211. Reinert T., Fiedler A., Morawski M., Arendt T. High resolution quantitative element mapping of neuromelanin-containing neurons. Nuclear Instruments & Methods in Physics Research Section B-Beam Interactions with Materials and Atoms 2007, 260(1):227-230.
212. Morawski M, Meinecke C, Reinert T, Dorffel AC, Riederer P, Arendt T, Butz T. Determination of trace elements in the human substantia nigra. Nuclear Instruments & Methods in Physics Research Section B-Beam Interactions with Materials and Atoms 2005;231 (1-4): 224-228.
213. Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF. 1995. The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci 1995: 134 (Suppl) 69-78.
214. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989, 52(6):1830-1836.